Article Text

PDF
Response to: ‘Metabolic and cardiovascular benefits of hydroxychloroquine: exploration in a wider population at high CV risk’ by Pareek et al
  1. Charlotte Hua,
  2. Claire Rempenault,
  3. Bernard Combe
  1. Rheumatology department, Lapeyronie Hospital, Montpellier University, Montpellier, Languedoc-Roussillon, France
  1. Correspondence to Dr Charlotte Hua, Département de Rhumatologie, CHU Lapeyronie, 191 Av. du Doyen Gaston Giraud, 34295 Montpellier cedex 5, France; c-hua{at}chu-montpellier.fr

Statistics from Altmetric.com

In their letter to the editor, Pareek et al raised some issues regarding our recent paper.1 2 We appreciate their interest in our study and their positive comments.

Pareek et al highlight the fact that several studies addressing the metabolic effect of hydroxychloroquine (HCQ) have not been included in our meta-analysis due to our stringent inclusion criteria (HCQ users vs non-users in patients with rheumatoid arthritis (RA)). We acknowledge …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles